Cite
HARVARD Citation
Blauvelt, A. et al. (n.d.). AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis. Annals of the rheumatic diseases. pp. 1602-1603. [Online].